Prognostic Histopathological and Molecular Markers on Prostate Cancer Needle-Biopsies: A Review

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Hoogland, A Marije ^a   Kweldam, Charlotte F ^a   Leenders, Geert J L H Van ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; KI 67 ANTIGEN; MOLECULAR MARKER; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR ERG; TUMOR MARKER;

BIOCHEMICAL RECURRENCE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CELL DIFFERENTIATION; CLINICAL DECISION MAKING; DISTANT METASTASIS; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MALE; NEEDLE BIOPSY; NEUROENDOCRINE TUMOR; PERINEURAL INVASION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE VOLUME; PROSTATECTOMY; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; METABOLISM; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS;

BIOMARKERS, TUMOR; BIOPSY, NEEDLE; HUMANS; MALE; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84922820734     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/341324     Document Type: Review

References (118)

1. J. I. Epstein, W. C. Allsbrook Jr., M. B. Amin et al., "The 2005 International Society ofUrological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma, " The American Journal of Surgical Pathology, vol. 29, no. 9, pp. 1228-1242, 2005.
2. T. van der Kwast, L. Bubendorf, C. Mazerolles et al., "Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European randomized study of screening for prostate cancer (ERSPC), " Virchows Archiv, vol. 463, no. 3, pp. 367-377, 2013.
3. M. R. Cooperberg, J. M. Broering, and P. R. Carroll, "Time trends and local variation in primary treatment of localized prostate cancer, " Journal of Clinical Oncology, vol. 28, no. 7, pp. 1117-1123, 2010.
4. M. R. Cooperberg, P. R. Carroll, and L. Klotz, "Active surveillance for prostate cancer: progress and promise, " Journal of Clinical Oncology, vol. 29, no. 27, pp. 3669-3676, 2011.
5. M. S. Soloway, C. T. Soloway, A. Eldefrawy, K. Acosta, B. Kava, and M. Manoharan, "Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment, " European Urology, vol. 58, no. 6, pp. 831-835, 2010.
6. J. J. Tosoian, B. J. Trock, P. Landis et al., "Active surveillance program for prostate cancer: an update of the Johns Hopkins experience, " Journal of Clinical Oncology, vol. 29, no. 16, pp. 2185-2190, 2011.
7. N. J. van As, A. R. Norman, K. Thomas et al., "Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance, " European Urology, vol. 54, no. 6, pp. 1297-1305, 2008.
8. R. C. N. van den Bergh, S. Roemeling, M. J. Roobol et al., "Outcomes ofmen with screen-detected prostate cancer eligible for active surveillance who were managed expectantly, " European Urology, vol. 55, no. 1, pp. 1-8, 2009.
9. L. Egevad, A. S. Ahmad, F. Algaba et al., "Standardization of Gleason grading among 337 European pathologists, " Histopathology, vol. 62, no. 2, pp. 247-256, 2013.
10. J. K. McKenney, J. Simko, M. Bonham et al., "The potential impact of reproducibility of gleason grading in men with early stage prostate cancer managed by active surveillance: a multiinstitutional study, " Journal of Urology, vol. 186, no. 2, pp. 465-469, 2011.
11. D. F. Gleason, "Classification of prostatic carcinomas., " Cancer Chemotherapy Reports, vol. 50, no. 3, pp. 125-128, 1966.
12. J. I. Epstein, "An update of the Gleason grading system, " Journal of Urology, vol. 183, no. 2, pp. 433-440, 2010.
13. M. Latour, M. B. Amin, A. Billis et al., "Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology, "TheAmerican Journal of Surgical Pathology, vol. 32, no. 10, pp. 1532-1539, 2008.
14. T. L. Lotan and J. I. Epstein, "Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy, " Human Pathology, vol. 40, no. 4, pp. 471-477, 2009.
15. A. Billis, M. S. Guimaraes, L. L. L. Freitas, L. Meirelles, L. A. Magna, and U. Ferreira, "The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies, " Journal of Urology, vol. 180, no. 2, pp. 548-553, 2008.
16. B. Helpap and L. Egevad, "The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens, " Virchows Archiv, vol. 449, no. 6, pp. 622-627, 2006.
17. P. Zareba, J. Zhang, A. Yilmaz, and K. Trpkov, "The impact of the 2005 International Society of Urological Pathology (ISUP) consensus on Gleason grading in contemporary practice, " Histopathology, vol. 55, no. 4, pp. 384-391, 2009.
18. H. Uemura, K. Hoshino, T. Sasaki et al., "Usefulness of the 2005 International Society of Urologic Pathology Gleason grading systemin prostate biopsy and radical prostatectomy specimens, " BJU International, vol. 103, no. 9, pp. 1190-1194, 2009.
19. J. I. Epstein, Z. Feng, B. J. Trock, and P. M. Pierorazio, "Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using themodified gleason grading system and factoring in tertiary grades, " European Urology, vol. 61, no. 5, pp. 1019-1024, 2012.
20. A. S. Moussa, M. W. Kattan, R. Berglund, C. Yu, K. Fareed, and J. S. Jones, "A nomogram for predicting upgrading in patients with low-and intermediate-grade prostate cancer in the era of extended prostate sampling, " BJU International, vol. 105, no. 3, pp. 352-358, 2010.
21. A. S. Moussa, J. Li, M. Soriano, E. A. Klein, F. Dong, and J. S. Jones, "Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer, " BJU International, vol. 103, no. 1, pp. 43-48, 2009.
22. H. Visapaa, K. Hotakainen, J. Lundin, M. Ala-Opas, and U. Stenman, "The proportion of free PSA and upgrading of biopsy gleason score after radical prostatectomy, " Urologia Internationalis, vol. 84, no. 4, pp. 378-381, 2010.
23. J. G. Phillips, A. A. Aizer, M. H. Chen et al., "The effect of differing gleason scores at biopsy on the odds of upgrading and the risk of death from prostate cancer, " Clinical Genitourinary Cancer, 2014.
24. J. M. Whitson, S. P. Porten, J. E. Cowan, J. P. Simko, M. R. Cooperberg, and P. R. Carroll, "Factors associated with downgrading in patients with high grade prostate cancer, " Urologic Oncology: Seminars and Original Investigations, vol. 31, no. 4, pp. 442-447, 2013.
25. P. M. Pierorazio, A. E. Ross, B. M. Lin et al., "Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy, " BJU International, vol. 110, no. 8, pp. 1122-1128, 2012.
26. J. Busch, K. Hamborg, H. Meyer et al., "Value of prostate specific antigen density and percent free prostate specific antigen for prostate cancer prognosis, " Journal of Urology, vol. 188, no. 6, pp. 2165-2170, 2012.
27. A. Forgues, F. Rozet, F. Audenet et al., "Oncologic outcomes after minimally invasive radical prostatectomy in patients with seminal vesicle invasion (pT3b) without adjuvant therapy, " World Journal of Urology, vol. 32, no. 2, pp. 519-524, 2014.
28. J. J. Meeks, A. C. Maschino, K. T. McVary, and J. S. Sandhu, "Clinically significant prostate cancer is rarely missed by ablative procedures of the prostate in men with prostate specific antigen less than 4 ng/ml, " Journal of Urology, vol. 189, no. 1, pp. 111-115, 2013.
29. M. K. Tollefson, R. J. Karnes, E. D. Kwon et al., "Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: theMayo model, "Mayo Clinic Proceedings, vol. 89, pp. 308-318, 2014.
30. E. W. Steyerberg, M. J. Roobol, M. W. Kattan, T. H. van der Kwast, H. J. de Koning, and F. H. Schroder, "Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram, " Journal of Urology, vol. 177, no. 1, pp. 107-112, 2007.
31. R. C. van den Bergh, H. U. Ahmed, C. H. Bangma, M. R. Cooperberg, A. Villers, and C. C. Parker, "Novel tools to improve patient selection andmonitoring on active surveillance for lowrisk prostate cancer: a systematic review, " EuropeanUrology, vol. 65, pp. 1023-1031, 2014.
32. M. A. DallEra, P. C. Albertsen, C. Bangma et al., "Active surveillance for prostate cancer: a systematic review of the literature, " European Urology, vol. 62, no. 6, pp. 976-983, 2012.
33. S. J. Freedland, W. J. Aronson, M. K. Terris et al., "The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database, " Cancer, vol. 98, no. 11, pp. 2344-2350, 2003.
34. S. J. Freedland, W. J. Aronson, M. K. Terris et al., "Percent of prostate needle biopsy cores with cancer is a significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from the SEARCH database, " Journal of Urology, vol. 169, no. 6, pp. 2136-2141, 2003.
35. P. W. Linson, A. K. Lee, T. Doytchinova et al., "Percentage of core lengths involved with prostate cancer: does it add to the percentage of positive prostate biopsies in predicting postoperative prostate-specific antigen outcome for men with intermediate-risk prostate cancer?" Urology, vol. 59, no. 5, pp. 704-708, 2002.
36. C. P. Nelson, R. L. Dunn, J. T. Wei, M. A. Rubin, J. E. Montie, and M. G. Sanda, "Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions, " Urologic Oncology, vol. 21, no. 3, pp. 213-218, 2003.
37. A. N. Vis, S. Roemeling, R. Kranse, F. H. Schroder, and T. H. van der Kwast, "Should we replace the Gleason score with the amount of high-grade prostate cancer?, " European Urology, vol. 51, no. 4, pp. 931-939, 2007.
38. S. M. Vance, M. H. Stenmark, K. Blas, S. Halverson, D. A. Hamstra, and F. Y. Feng, "Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy, " International Journal of Radiation Oncology Biology Physics, vol. 83, no. 3, pp. 940-946, 2012.
39. S. G. Williams, M. K. Buyyounouski, T. Pickles et al., "Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3, 264 men: statistical significance without predictive performance, " International Journal of Radiation Oncology Biology Physics, vol. 70, no. 4, pp. 1169-1175, 2008.
40. S. J. Freedland, M. K. Terris, G. S. Csathy et al., "Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen, " The Journal of Urology, vol. 171, no. 6 I, pp. 2215-2220, 2004.
41. H. Huland, P. Hammerer, R. Henke, and E. Huland, "Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal examination, prostate specific antigen and the results of 6 systematic biopsies, " Journal of Urology, vol. 155, no. 4, pp. 1344-1347, 1996.
42. V. Ravery, C. Chastang, M. Toublanc, L. Boccon-Gibod, and V. Delmas, "Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer, " European Urology, vol. 37, no. 4, pp. 449-455, 2000.
43. J. Huang, F. A. Vicini, S. G. Williams et al., "Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?" International Journal of Radiation Oncology, Biology, Physics, vol. 83, no. 4, pp. 1141-1148, 2012.
44. S. Karram, B. J. Trock, G. J. Netto, andJ. I. Epstein, "Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings, " The American Journal of Surgical Pathology, vol. 35, no. 9, pp. 1351-1355, 2011.
45. L. Schultz, C. E. Maluf, R. C. da Silva, H. Falashi Rde, M. V. da Costa, and M. I. Schultz, "Discontinuous foci of cancer in a single core of prostatic biopsy: when it occurs and performance of quantification methods in a private-practice setting, "American Journal of Surgical Pathology, vol. 37, pp. 1831-1836, 2013.
46. T. H. van der Kwast and M. J. Roobol, "Defining the threshold for significant versus insignificant prostate cancer, " Nature Reviews Urology, vol. 10, no. 8, pp. 473-482, 2013.
47. P. Harnden, M. D. Shelley, H. Clements et al., "The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review, " Cancer, vol. 109, no. 1, pp. 13-24, 2007.
48. M. A. Rubin, T. A. Bismar, S. Curtis, and J. E. Montie, "Prostate needle biopsy reporting: how are the surgical members of the society of urologic oncology using pathology reports to guide treatment of prostate cancer patients?" American Journal of Surgical Pathology, vol. 28, no. 7, pp. 946-952, 2004.
49. D. I. Quinn, S. M. Henshall, P. C. Brenner et al., "Prognostic significance of preoperative factors in localized prostatecarcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion, " Cancer, vol. 97, no. 8, pp. 1884-1893, 2003.
50. J. O. Delancey, D. P. Wood Jr., C. He et al., "Evidence of perineural invasion on prostate biopsy specimen and survival after radical prostatectomy, " Urology, vol. 81, no. 2, pp. 354-357, 2013.
51. M. Pickup and T. H. Van Der Kwast, "My approach to intraductal lesions of the prostate gland, " Journal of Clinical Pathology, vol. 60, no. 8, pp. 856-865, 2007.
52. B. D. Robinson and J. I. Epstein, "Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: Emphasis on radical prostatectomy findings, " Journal of Urology, vol. 184, no. 4, pp. 1328-1333, 2010.
53. R. J. Cohen, W. C. Chan, S. G. Edgar et al., "Prediction of pathological stage and clinical outcome in prostate cancer: an improved pre-operative model incorporating biopsy-determined intraductal carcinoma, " British Journal of Urology, vol. 81, no. 3, pp. 413-418, 1998.
54. E. Efstathiou, N. A. Abrahams, R. F. Tibbs et al., "Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification, " European Urology, vol. 57, no. 6, pp. 1030-1038, 2010.
55. T. van der Kwast, N. Al Daoud, L. Collette et al., "Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy, " European Journal of Cancer, vol. 48, no. 9, pp. 1318-1325, 2012.
56. J. I. Epstein, "Prostatic ductal adenocarcinoma: a mini review, " Medical Principles and Practice, vol. 19, no. 1, pp. 82-85, 2010.
57. F. Dong, P. Yang, C. Wang et al., "Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma, " American Journal of Surgical Pathology, vol. 37, pp. 1855-1861, 2013.
58. D. M. Berney, F. Algaba, P. Camparo et al., "Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologists, " Virchows Archiv, vol. 464, pp. 583-587, 2014.
59. A. Sica, T. Schioppa, A. Mantovani, and P. Allavena, "Tumourassociated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy, " European Journal of Cancer, vol. 42, no. 6, pp. 717-727, 2006.
60. N. Nonomura, H. Takayama, M. Nakayamaet al., "Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer, " BJU International, vol. 107, no. 12, pp. 1918-1922, 2011.
61. G. Fisher, Z. H. Yang, S. Kudahetti et al., "Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort, " British Journal of Cancer, vol. 108, no. 2, pp. 271-277, 2013.
62. J. Rubio, D. Ramos, J. A. Lopez-Guerrero et al., "Immunohistochemical expression of Ki-67 antigen, Cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens, " European Urology, vol. 48, no. 5, pp. 745-751, 2005.
63. T. T. Tolonen, T. L. J. Tammela, P. M. Kujala, V. J. Tuominen, J. J. Isola, and T. Visakorpi, "Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer, " BJU International, vol. 108, no. 9, pp. 1430-1438, 2011.
64. A. N. Vis, B. W. G. vanRhijn, M. A. Noordzij, F. H. Schroder, and T. H. van der Kwast, "Value of tissue markers p27kip1, MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer, " The Journal of Pathology, vol. 197, no. 2, pp. 148-154, 2002.
65. T. Wolters, K. J. Vissers, C. H. Bangma, F. H. Schroder, and G. J. L. H. Van Leenders, "The value of EZH2, p27kip1, BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selectingmen with significant prostate cancer at prostatectomy, " BJU International, vol. 106, no. 2, pp. 280-286, 2010.
66. T. Zellweger, S. Gunther, I. Zlobec et al., "Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer, " International Journal of Cancer, vol. 124, no. 9, pp. 2116-2123, 2009.
67. G. V. Thomas, M. I. Schrage, L. Rosenfelt et al., "Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, gleason grade and pathological stage, " Journal of Urology, vol. 164, no. 6, pp. 1987-1991, 2000.
68. W. R. Sellers and M. Loda, "TheEZH2 polycomb transcriptional repressor-a marker or mover of metastatic prostate cancer?" Cancer Cell, vol. 2, no. 5, pp. 349-350, 2002.
69. S. Varambally, S. M. Dhanasekaran, M. Zhou et al., "The polycomb group protein EZH2 is involved in progression of prostate cancer, " Nature, vol. 419, no. 6907, pp. 624-629, 2002.
70. C. Behrens, L. M. Solis, H. Lin et al., "EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma, " Clinical Cancer Research, vol. 19, pp. 6556-6565, 2013.
71. G. Deb, V. S. Thakur, and S. Gupta, "Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond, " Epigenetics, vol. 8, no. 5, pp. 464-476, 2013.
72. S. Roh, S. Y. Park, H. S. Ko, J. S. Sohn, and E. J. Cha, "EZH2 expression in invasive lobular carcinoma of the breast, " World Journal of Surgical Oncology, vol. 11, p. 299, 2013.
73. Y. Liu, T. Liu, X. Bao, M. He, L. Li, andX. Yang, "Increased EZH2 expression is associated with proliferation and progression of cervical cancer and indicates a poor prognosis, " The International Journal of Gynecological Pathology, vol. 33, pp. 218-224, 2014.
74. A. Hayashi, T. Morikawa, T. Kawai et al., "Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma, " Virchows Archiv, vol. 464, pp. 463-471, 2014.
75. H. J. Lee, D. H. Shin, K. B. Kim et al., "Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, " Leukemia and Lymphoma, 2014.
76. A. M. Hoogland, E. I. Verhoef, M. J. Roobol et al., "Validation of stem cell markers in clinical prostate cancer: alpha6-integrin is predictive for non-aggressive disease, " Prostate, vol. 74, pp. 488-496, 2014.
77. S. Laitinen, P. M. Martikainen, T. Tolonen, J. Isola, T. L. J. Tammela, andT. Visakorpi, "EZH2, Ki-67 andMCM7 are prognostic markers in prostatectomy treated patients, " International Journal of Cancer, vol. 122, no. 3, pp. 595-602, 2008.
78. G. J. L. H. van Leenders, D. Dukers, D. Hessels et al., "Polycombgroup oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features, " European Urology, vol. 52, no. 2, pp. 455-463, 2007.
79. S. A. Tomlins, D. R. Rhodes, S. Perner et al., "Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer, " Science, vol. 310, no. 5748, pp. 644-648, 2005.
80. R. B. Shah, "Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management, " Advances in Anatomic Pathology, vol. 20, no. 2, pp. 117-124, 2013.
81. D. Hossain and D. G. Bostwick, "Significance of the TMPRSS2 :ERG gene fusion in prostate cancer, " BJU International, vol. 111, no. 5, pp. 834-835, 2013.
82. D. Hessels and J. A. Schalken, "Recurrent gene fusions in prostate cancer: their clinical implications and uses, " Current Urology Reports, vol. 14, no. 3, pp. 214-222, 2013.
83. B. Xu, M. Chevarie-Davis, S. Chevalier et al., "The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature, " Human Pathology, vol. 45, pp. 488-497, 2014.
84. J. P. Clark and C. S. Cooper, "ETS gene fusions in prostate cancer, "Nature ReviewsUrology, vol. 6, no. 8, pp. 429-439, 2009.
85. B. Furusato, S. Tan, D. Young et al., "ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification, " Prostate Cancer and Prostatic Diseases, vol. 13, no. 3, pp. 228-237, 2010.
86. A. M. Hoogland, G. Jenster, W. M. van Weerden et al., "ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer, " Modern Pathology, vol. 25, no. 3, pp. 471-479, 2012.
87. M. Miettinen, Z. F. Wang, A. Paetau et al., "ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma, " The American Journal of Surgical Pathology, vol. 35, no. 3, pp. 432-441, 2011.
88. K. Park, S. A. Tomlins, K. M. Mudaliar et al., "Antibody-based detection of ERG rearrangement-positive prostate cancer, " Neoplasia, vol. 12, no. 7, pp. 590-598, 2010.
89. O. R. Saramaki, A. E. Harjula, P. M. Martikainen, R. Lvessella, T. L. J. Tammela, and T. Visakorpi, "TMPRSS2. ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis, " Clinical Cancer Research, vol. 14, no. 11, pp. 3395-3400, 2008.
90. V. J. Scheble, G. Scharf, M. Braun et al., "ERG rearrangement in local recurrences compared to distant metastases of castrationresistant prostate cancer, " Virchows Archiv, vol. 461, no. 2, pp. 157-162, 2012.
91. S. A. Tomlins, B. Laxman, S. Varambally et al., "Role of the TMPRSS2-ERG gene fusion in prostate cancer, " Neoplasia, vol. 10, no. 2, pp. 177-188, 2008.
92. G. J. van Leenders, J. L. Boormans, C. J. Vissers et al., "Antibody EPR3864 is specific for ERGgenomic fusions in prostate cancer: implications for pathological practice, " Modern Pathology, vol. 24, no. 8, pp. 1128-1138, 2011.
93. J. D. Barros-Silva, F. R. Ribeiro, A. Rodrigues et al., "Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer, " Genes Chromosomes and Cancer, vol. 50, no. 8, pp. 662-671, 2011.
94. C. Andrews and P. A. Humphrey, "Utility of ERG versus AMACR expression in diagnosis of minimal adenocarcinoma of the prostate in needle biopsy tissue, " The American Journal of Surgical Pathology, vol. 38, pp. 1007-1012, 2014.
95. A. Bjartell, R. Montironi, D. M. Berney, andL. Egevad, "Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers, " Acta Oncologica, vol. 50, 1, pp. 76-84, 2011.
96. C. Boran, E. Kandirali, F. Yilmaz, E. Serin, and M. Akyol, "Reliability of the 34βE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma, " Urologic Oncology: Seminars and Original Investigations, vol. 29, no. 6, pp. 614-623, 2011.
97. P. D. Dabir, P. Ottosen, S. Hoyer, and S. Hamilton-Dutoit, "Comparative analysis of three-and two-antibody cocktails to AMACR and basal cell markers for the immunohistochemical diagnosis of prostate carcinoma, " Diagnostic Pathology, vol. 7, no. 1, article 81, 2012.
98. K. Pavlakis, K. Stravodimos, T. Kapetanakis et al., "Evaluationof routine application of P504S, 34βE12 and p63 immunostaining on 250 prostate needle biopsy specimens, " International Urology and Nephrology, vol. 42, no. 2, pp. 325-330, 2010.
99. R. B. Shah, L. P. Kunju, R. Shen, M. LeBlanc, M. Zhou, and M. A. Rubin, "Usefulness of basal cell cocktail (34βE12 + p63) in the diagnosis of atypical prostate glandular proliferations, " American Journal of Clinical Pathology, vol. 122, no. 4, pp. 517-523, 2004.
100. K. D. Berg, B. Vainer, F. B. Thomsen et al., "ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer, " European Urology, 2014.
101. C. Hagglof, P. Hammarsten, K. Stromvall et al., "TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers, " PLoS One, vol. 9, Article IDe86824, 2014.
102. K. Park, J. T. Dalton, R. Narayanan et al., "TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia, " Journal of Clinical Oncology, vol. 32, pp. 206-211, 2014.
103. P.-A. Abrahamsson, "Neuroendocrine cells in tumour growth of the prostate, " Endocrine-Related Cancer, vol. 6, no. 4, pp. 503-519, 1999.
104. P. A. di SantAgnese, "Neuroendocrine differentiation in carcinoma of the prostate: diagnostic, prognostic, and therapeutic implications, " Cancer, vol. 70, no. 1, pp. 254-268, 1992.
105. P. A. Di SantAgnese and A. T. K. Cockett, "The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research, " Journal of Urology, vol. 152, no. 5, pp. 1927-1931, 1994.
106. D. J. Krauss, M. Amin, B. Stone et al., "ChromograninAstaining as a prognostic variable in newly diagnosed Gleason score 7 prostate cancer treated with definitive radiotherapy, " The Prostate, vol. 74, no. 5, pp. 520-527, 2014.
107. D. J. Krauss, S. Hayek, M. Amin et al., "Prognostic significance of neuroendocrine differentiation in patients with gleason score 8-10 prostate cancer treated with primary radiotherapy, " International Journal of Radiation Oncology Biology Physics, vol. 81, no. 3, pp. e119-e125, 2011.
108. L. M. Boxer and C. V. Dang, "Translocations involving c-myc and c-myc function, " Oncogene, vol. 20, no. 40, pp. 5595-5610, 2001.
109. B. Gurel, T. Iwata, C. M. Koh et al., "Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis, " Modern Pathology, vol. 21, no. 9, pp. 1156-1167, 2008.
110. F. R. Ribeiro, R. Henrique, A. T. Martins, C. Jeronimo, and M. R. Teixeira, "Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients, " European Urology, vol. 52, pp. 116-125, 2007.
111. G. Zafarana, A. S. Ishkanian, C. A. Malloff et al., "Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy, " Cancer, vol. 118, no. 16, pp. 4053-4062, 2012.
112. S. Bastacky, K. Cieply, C. Sherer, R. Dhir, andJ. I. Epstein, "Useof interphase fluorescence in situ hybridization in prostate needle biopsy specimens with isolated high-grade prostatic intraepithelial neoplasia as a predictor of prostate adenocarcinoma on follow-up biopsy, " Human Pathology, vol. 35, no. 3, pp. 281-289, 2004.
113. C. C. Uzoh, C. M. Perks, A. Bahl, J. M. P. Holly, M. Sugiono, and R. A. Persad, "PTEN-mediated pathways and their association with treatment-resistant prostate cancer, " BJU International, vol. 104, no. 4, pp. 556-561, 2009.
114. J. Cuzick, Z. H. Yang, G. Fisher et al., "Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer, " British Journal of Cancer, vol. 108, no. 12, pp. 2582-2589, 2013.
115. R. Henrique, F. R. Ribeiro, D. Fonseca et al., "High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients, " Clinical Cancer Research, vol. 13, no. 20, pp. 6122-6129, 2007.
116. E. A. Klein, M. R. Cooperberg, C. Magi-Galluzzi et al., "A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling, " European Urology, vol. 66, no. 3, pp. 550-560, 2014.
117. S. Irshad, M. Bansal, M. Castillo-Martin et al., "A molecular signature predictive of indolent prostate cancer, " Science Translational Medicine, vol. 5, no. 202, p. 202ra122, 2013.
118. A. M. Hoogland, A. Dahlman, K. J. Vissers et al., "Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome, " BJU International, vol. 108, no. 8, pp. 1356-1362, 2011.